Alpine Immune Sciences (NASDAQ:ALPN) and Corvus Pharmaceuticals (NASDAQ:CRVS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, dividends and profitability.
Insider & Institutional Ownership
52.9% of Alpine Immune Sciences shares are owned by institutional investors. Comparatively, 60.8% of Corvus Pharmaceuticals shares are owned by institutional investors. 76.1% of Alpine Immune Sciences shares are owned by insiders. Comparatively, 45.1% of Corvus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Volatility & Risk
Alpine Immune Sciences has a beta of 1.72, suggesting that its share price is 72% more volatile than the S&P 500. Comparatively, Corvus Pharmaceuticals has a beta of 1.81, suggesting that its share price is 81% more volatile than the S&P 500.
Profitability
This table compares Alpine Immune Sciences and Corvus Pharmaceuticals' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
|---|
| Alpine Immune Sciences | -606.16% | -80.38% | -30.76% |
| Corvus Pharmaceuticals | N/A | -79.15% | -63.99% |
Earnings & Valuation
This table compares Alpine Immune Sciences and Corvus Pharmaceuticals' revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
|---|
| Alpine Immune Sciences | $1.74 million | 177.15 | $-41,850,000.00 | ($2.28) | -5.68 |
| Corvus Pharmaceuticals | N/A | N/A | $-46,670,000.00 | ($1.59) | -1.80 |
Alpine Immune Sciences has higher revenue and earnings than Corvus Pharmaceuticals. Alpine Immune Sciences is trading at a lower price-to-earnings ratio than Corvus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of recent ratings for Alpine Immune Sciences and Corvus Pharmaceuticals, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
|---|
| Alpine Immune Sciences | 0 | 0 | 6 | 0 | 3.00 |
| Corvus Pharmaceuticals | 0 | 1 | 2 | 0 | 2.67 |
Alpine Immune Sciences presently has a consensus price target of $19.40, suggesting a potential upside of 49.81%. Corvus Pharmaceuticals has a consensus price target of $8.00, suggesting a potential upside of 179.72%. Given Corvus Pharmaceuticals' higher possible upside, analysts clearly believe Corvus Pharmaceuticals is more favorable than Alpine Immune Sciences.
Summary
Corvus Pharmaceuticals beats Alpine Immune Sciences on 7 of the 13 factors compared between the two stocks.
